Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer

Changhoon Yoo, Sung Bae Kim, Jungsil Ro, Seock Ah Im, Young Hyuck Im, Jee Hyun Kim, Jin Hee Ahn, Kyung Hae Jung, Hong Suk Song, Seok Yun Kang, Hee Sook Park, Hyun Cheol Chung

Research output: Contribution to journalArticle

Abstract

Purpose This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. Materials and Methods A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). Results In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGFAA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p <.001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. Conclusion Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.

Original languageEnglish
Pages (from-to)499-507
Number of pages9
JournalCancer Research and Treatment
Volume48
Issue number2
DOIs
Publication statusPublished - 2016 Apr 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Yoo, C., Kim, S. B., Ro, J., Im, S. A., Im, Y. H., Kim, J. H., Ahn, J. H., Jung, K. H., Song, H. S., Kang, S. Y., Park, H. S., & Chung, H. C. (2016). Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer. Cancer Research and Treatment, 48(2), 499-507. https://doi.org/10.4143/crt.2015.089